CSSP Webinar

This forum will discuss evidence-based operative standards for the performance of breast cancer surgery as outlined in the Operative Standards for Cancer Surgery, Volume 1. This will include review of technical standards and the rationale supporting these recommendations. The discussion will include insights into clinical management of breast cancer and applicable controversies.

At the completion of the activity, participants should be able to:

• Recognize the key operative standards for the performance of partial mastectomy, total mastectomy, axillary lymphadenectomy, and sentinel lymphadenectomy endorsed by the American College of Surgeons Cancer Research Program and Cancer Surgery Standards Program.
• Illustrate evidence-based rationale for these standards and how they impact patient outcomes.
• Demonstrate competence in the description of technical aspects of the operative standards.
• Apply insight into contemporary breast cancer management including clinical controversies.

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as “ineligible companies”, defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

• Ineligible Company: The ACCME defines an “ineligible company” as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.
• Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
• Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

Kelly Hunt, MD – Research support from Cairn Surgical, Eli Lilly & Co., and Lumicell. Medical Advisory Board member AmadaHealth, AstraZenica, Merck & Co. 

Katharine Yao, MD - (Nothing to disclose)

Puneet Singh, MD - (Nothing to disclose)

Lyndsey Kilgore, MD - (Nothing to disclose)

Makesha Miggins, MD - (Nothing to disclose)

Mediget Teshome, MD - Conference attendance at the transatlantic breast cancer conference.

Puneet Singh, MD - (Nothing to disclose)

Lyndsey Kilgore, MD – (Nothing to disclose)

Elizabeth Funk, MSW - (Nothing to disclose)

Peter Carpenter, MHA - (Nothing to disclose)